Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

5.210 +0.340 (+6.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 940,708
Open 4.890
Bid (Size) 4.000 (2)
Ask (Size) 5.510 (10)
Prev. Close 4.870
Today's Range 4.790 - 5.225
52wk Range 4.610 - 20.04
Shares Outstanding 93,097,679
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Where Atara Biotherapeutics Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Atara Biotherapeutics (NASDAQ:ATRA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
 
Via Benzinga

Performance

YTD
-68.88%
-68.88%
1 Month
-22.47%
-22.47%
3 Month
-59.46%
-59.46%
6 Month
-70.71%
-70.71%
1 Year
-61.58%
-61.58%

More News

Read More
HC Wainwright & Co. Maintains Buy Rating for Atara Biotherapeutics: Here's What You Need To Know
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
Via Benzinga
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Earnings Preview
Via Benzinga
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
From Atara Biotherapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Via Benzinga
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Host EBV and MS Day
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
80 Biggest Movers From Yesterday
Via Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.